Neracorvir

Neracorvir
Clinical data
Other namesGST-HG141
Legal status
Legal status
  • investigational
Identifiers
  • N-[2-[(2S)-1,4-dioxan-2-yl]ethyl]-2-methyl-4,10,10-trioxo-5H-pyrrolo[1,2-b][1,2,5]benzothiadiazepine-7-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaC19H21N3O6S
Molar mass419.45 g·mol−1
3D model (JSmol)
  • CC1=CN2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC[C@H]4COCCO4
  • InChI=InChI=1S/C19H21N3O6S/c1-12-8-16-19(24)21-15-9-13(2-3-17(15)29(25,26)22(16)10-12)18(23)20-5-4-14-11-27-6-7-28-14/h2-3,8-10,14H,4-7,11H2,1H3,(H,20,23)(H,21,24)/t14-/m0/s1
  • Key:OXJNOWPZKFUKNS-AWEZNQCLSA-N

Neracorvir is an investigational new drug that is being evaluated by Fujian Cosunter Pharmaceutical Company, Ltd. for the treatment of chronic hepatitis B virus (HBV) infections. It binds to the hepatitis B core (capsid) protein interfering with hepatitis B capsid assembly and viral replication.[1][2] Neracorvir is sometimes referred to as a HBV core protein modulator,[3] but in HBV, the core and capsid proteins are one in the same.[4]

Clinical trials

Neracorvir is currently in phase 3 clinical trials for chronic hepatitis B infection.[5]

See also

References

  1. ↑ "Neracorvir - Fujian Cosunter Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Chen Z, Hu R, Ye H, Chen Q, Liu Y, Zhang X, et al. (2026). "Innate immune recognition and evasion strategies of hepatitis B virus: from DNA to RNA and viral proteins". Frontiers in Immunology. 17 1741620. doi:10.3389/fimmu.2026.1741620. PMC 13003344. PMID 41869349.
  3. ↑ "Fujian Cosunter Pharmaceutical's new drug for hepatitis B, which reduces cccDNA transcription activity, has published its Phase II research findings in an authoritative international journal". Moomoo Technologies Inc. 4 August 2025.
  4. ↑ Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S (September 2015). "Core protein: A pleiotropic keystone in the HBV lifecycle". Antiviral Research. 121: 82–93. doi:10.1016/j.antiviral.2015.06.020. PMC 4537649. PMID 26129969.
  5. ↑ Clinical trial number NCT07090759 for "To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment" at ClinicalTrials.gov
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.